Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function

NCT ID: NCT01961453

Last Updated: 2016-08-11

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2016-01-31

Brief Summary

The purpose of this research study is to test whether treatment with isosorbide mononitrate will improve left ventricular hypertrophy ("thickening") which puts people at risk for developing heart failure. Once it develops, heart failure is a very serious condition and thus it is important to find ways to prevent it from happening. The investigators have reasons to believe that dilating the blood vessels with this specific medication will improve the thickening of the heart, which increases the risk of heart failure.

Conditions

Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Isosorbide Mononitrate, sustained release

One tablet containing 60 mg (Titration Stage 1) OR 120 mg (Titration Stage 2) of sustained-release ISMN administered at 8 AM.

Group Type: ACTIVE_COMPARATOR

Isosorbide Mononitrate, sustained release

Intervention Type: DRUG

60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2

Placebo capsule

One capsule of placebo administered once daily at 8 AM

Group Type: PLACEBO_COMPARATOR

Placebo capsule

Intervention Type: DRUG

One capsule of placebo administered once daily at 8 am.

Interventions

Isosorbide Mononitrate, sustained release

60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2

Intervention Type: DRUG

Placebo capsule

One capsule of placebo administered once daily at 8 am.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Systolic blood pressure >140 mmHg, diastolic blood pressure > 90 mmHg.
• An elevated left ventricular mass index (defined as >60 g/m1.7 in women and 80 g/m1.7 in men) OR LV posterior wall thickness >1.4 cm documented in a clinically indicated echocardiographic examination or magnetic resonance imaging scan within the previous 12 months.
• Stable medical therapy as defined by: (1)No addition or removal of ACE inhibitors, angiotensin receptor blockers, beta-blockers, or calcium channel blockers for 30 days. (2)No change in dosage of ACE, angiotensin-receptor blocker, beta-blockers or calcium-channel blockers s of more than 100% for 30 days.
• Current therapy with an ACE inhibitor, hydralazine or a statin, all of which have been shown to reduce nitrate tolerance.

Exclusion Criteria

• Rhythm other than sinus rhythm (i.e., atrial fibrillation).
• Non-cardiac condition limiting life expectancy to less than one year, per physician judgment.
• Current or anticipated future need for nitrate therapy.
• Valve disease (> mild aortic or mitral stenosis; > moderate aortic or mitral regurgitation).
• Hypertrophic cardiomyopathy.
• Known infiltrative or inflammatory myocardial disease (amyloid, sarcoid).
• Pericardial disease.
• Primary pulmonary arteriopathy.
• Have experienced a myocardial infarction or unstable angina, or have undergone percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass grafting (CABG) within 60 days prior to consent, or requires either PTCA or CABG at the time of consent.
• Resting heart rate (HR) > 100 bpm.
• A reduced LV ejection fraction (EF<50%).
• Known severe liver disease (AST > 3x normal, alkaline phosphatase or bilirubin > 2x normal).
• Patients with a clinically indicated stress test demonstrating significant ischemia within a year of enrollment which was not followed by percutaneous or surgical revascularization.
• Allergy to isosorbide mononitrate.
• Current therapy with phosphodiesterase inhibitors, such as sildenafil, vardenafil or tadalafil, since the combination of nitrates and phosphodiesterase inhibitors can result in severe hypotension.
• Therapy with rosiglitazone, since this combination is not recommended based on epidemiologic data suggesting that it may increase the risk of myocardial ischemia.
• Current pregnancy or a positive urine pregnancy test. Women who become pregnant during the study will be discontinued from the trial.
• Contraindications to a cardiac MRI: (i) Central nervous system aneurysm clips; (ii) Implanted neural stimulators; (iii) Implanted cardiac pacemaker or defibrillator; (iv) Cochlear implant; (v) Ocular foreign body (e.g. metal shavings); (vi) Other implanted medical devices: (e.g. drug infusion ports); (vii) Insulin pump; (viii) Metal shrapnel or bullet; (ix) Claustrophobia; (x) Extreme obesity rendering the patient unable to fit into narrow-bore scanners; (xi) Unwillingness of the patient to undergo a cardiac MRI. All patients with metallic implants will be individually evaluated prior to MRI.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 89 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Corporal Michael J. Crescenz VA Medical Center

FED

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Julio A Chirinos, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Philadelphia VA Medical Center & University of Pennsylvania

Locations

Philadelphia VA Medical Center

Philadelphia, Pennsylvania, United States

Countries

United States

References

Bradley JG, Davis KA. Orthostatic hypotension. Am Fam Physician. 2003 Dec 15;68(12):2393-8.

Reference Type: BACKGROUND

PMID: 14705758 (View on PubMed)

Li H, Wang SX. Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate. J Nephrol. 2011 Mar-Apr;24(2):236-45. doi: 10.5301/jn.2011.6252.

Reference Type: BACKGROUND

PMID: 21240870 (View on PubMed)

Other Identifiers

01442

Identifier Type: -

Identifier Source: org_study_id